Abstract
Summary
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes TSH. Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
LPI (LP Information)' newest research report, the “Lanreotide Injection Industry Forecast” looks at past sales and reviews total world Lanreotide Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Lanreotide Injection sales for 2023 through 2029. With Lanreotide Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lanreotide Injection industry.
This Insight Report provides a comprehensive analysis of the global Lanreotide Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lanreotide Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Lanreotide Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lanreotide Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lanreotide Injection.
The global Lanreotide Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Lanreotide Injection players cover Ipsen and Cipla etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Lanreotide Injection market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Sustained Release Formulation
Long-acting Formula
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ipsen
Cipla
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lanreotide Injection market?
What factors are driving Lanreotide Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lanreotide Injection market opportunities vary by end market size?
How does Lanreotide Injection break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Lanreotide Injection Industry Forecast” looks at past sales and reviews total world Lanreotide Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Lanreotide Injection sales for 2023 through 2029. With Lanreotide Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lanreotide Injection industry.
This Insight Report provides a comprehensive analysis of the global Lanreotide Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lanreotide Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Lanreotide Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lanreotide Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lanreotide Injection.
The global Lanreotide Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Lanreotide Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Lanreotide Injection players cover Ipsen and Cipla etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Lanreotide Injection market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Sustained Release Formulation
Long-acting Formula
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Ipsen
Cipla
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lanreotide Injection market?
What factors are driving Lanreotide Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lanreotide Injection market opportunities vary by end market size?
How does Lanreotide Injection break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lanreotide Injection Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Lanreotide Injection by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Lanreotide Injection by Country/Region, 2018, 2022 & 2029
2.2 Lanreotide Injection Segment by Type
2.2.1 Sustained Release Formulation
2.2.2 Long-acting Formula
2.3 Lanreotide Injection Sales by Type
2.3.1 Global Lanreotide Injection Sales Market Share by Type (2018-2023)
2.3.2 Global Lanreotide Injection Revenue and Market Share by Type (2018-2023)
2.3.3 Global Lanreotide Injection Sale Price by Type (2018-2023)
2.4 Lanreotide Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Lanreotide Injection Sales by Application
2.5.1 Global Lanreotide Injection Sale Market Share by Application (2018-2023)
2.5.2 Global Lanreotide Injection Revenue and Market Share by Application (2018-2023)
2.5.3 Global Lanreotide Injection Sale Price by Application (2018-2023)
3 Global Lanreotide Injection by Company
3.1 Global Lanreotide Injection Breakdown Data by Company
3.1.1 Global Lanreotide Injection Annual Sales by Company (2018-2023)
3.1.2 Global Lanreotide Injection Sales Market Share by Company (2018-2023)
3.2 Global Lanreotide Injection Annual Revenue by Company (2018-2023)
3.2.1 Global Lanreotide Injection Revenue by Company (2018-2023)
3.2.2 Global Lanreotide Injection Revenue Market Share by Company (2018-2023)
3.3 Global Lanreotide Injection Sale Price by Company
3.4 Key Manufacturers Lanreotide Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lanreotide Injection Product Location Distribution
3.4.2 Players Lanreotide Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Lanreotide Injection by Geographic Region
4.1 World Historic Lanreotide Injection Market Size by Geographic Region (2018-2023)
4.1.1 Global Lanreotide Injection Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Lanreotide Injection Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Lanreotide Injection Market Size by Country/Region (2018-2023)
4.2.1 Global Lanreotide Injection Annual Sales by Country/Region (2018-2023)
4.2.2 Global Lanreotide Injection Annual Revenue by Country/Region (2018-2023)
4.3 Americas Lanreotide Injection Sales Growth
4.4 APAC Lanreotide Injection Sales Growth
4.5 Europe Lanreotide Injection Sales Growth
4.6 Middle East & Africa Lanreotide Injection Sales Growth
5 Americas
5.1 Americas Lanreotide Injection Sales by Country
5.1.1 Americas Lanreotide Injection Sales by Country (2018-2023)
5.1.2 Americas Lanreotide Injection Revenue by Country (2018-2023)
5.2 Americas Lanreotide Injection Sales by Type
5.3 Americas Lanreotide Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lanreotide Injection Sales by Region
6.1.1 APAC Lanreotide Injection Sales by Region (2018-2023)
6.1.2 APAC Lanreotide Injection Revenue by Region (2018-2023)
6.2 APAC Lanreotide Injection Sales by Type
6.3 APAC Lanreotide Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lanreotide Injection by Country
7.1.1 Europe Lanreotide Injection Sales by Country (2018-2023)
7.1.2 Europe Lanreotide Injection Revenue by Country (2018-2023)
7.2 Europe Lanreotide Injection Sales by Type
7.3 Europe Lanreotide Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lanreotide Injection by Country
8.1.1 Middle East & Africa Lanreotide Injection Sales by Country (2018-2023)
8.1.2 Middle East & Africa Lanreotide Injection Revenue by Country (2018-2023)
8.2 Middle East & Africa Lanreotide Injection Sales by Type
8.3 Middle East & Africa Lanreotide Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lanreotide Injection
10.3 Manufacturing Process Analysis of Lanreotide Injection
10.4 Industry Chain Structure of Lanreotide Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lanreotide Injection Distributors
11.3 Lanreotide Injection Customer
12 World Forecast Review for Lanreotide Injection by Geographic Region
12.1 Global Lanreotide Injection Market Size Forecast by Region
12.1.1 Global Lanreotide Injection Forecast by Region (2024-2029)
12.1.2 Global Lanreotide Injection Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Lanreotide Injection Forecast by Type
12.7 Global Lanreotide Injection Forecast by Application
13 Key Players Analysis
13.1 Ipsen
13.1.1 Ipsen Company Information
13.1.2 Ipsen Lanreotide Injection Product Portfolios and Specifications
13.1.3 Ipsen Lanreotide Injection Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Ipsen Main Business Overview
13.1.5 Ipsen Latest Developments
14 Research Findings and Conclusion